Education
About Us
Working with TipRanks
Follow Us
Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
OTLC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume643.67K
Average Volume (3M)190.61K
Market Cap
$30.88M
Enterprise Value$32.89M
Total Cash (Recent Filing)$88.02K
Total Debt (Recent Filing)$17.16M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Nov 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding434,929,960
10 Day Avg. Volume461,911
30 Day Avg. Volume190,606
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-19.12
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $30.88M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Nov 24, 2025 which is in 54 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Oncotelic Therapeutics released its earnings results on Aug 25, 2025. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 434,929,960 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Oncotelic Therapeutics reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Technical Analysis
Tempest Therapeutics
―
Pulmatrix
―
Annovis Bio
―
Elevation Oncology
―
Cognition Therapeutics
―
Ownership Overview
Options Prices
Currently, No data available
---